Nymox Pharmaceutical CorpOTC Pink - Current Information:NYMXF
- LAST PRICE0.0520
- TODAY'S CHANGE (%)0.0020 (4.0000%)
- Bid / Lots0.0210/ 100
- Ask / Lots0.2000/ 25
- Open / Previous Close0.0520 / 0.0500
- Day Range
- 52 Week Range
- Volume520
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NYMXF |
|---|---|---|
| 12:24 ET | 490 | 0.052 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nymox Pharmaceutical Corp | 4.7M | -0.5x | --- |
Check Cap Ltd | 4.7M | -0.3x | --- |
Portage Biotech Inc | 4.7M | -0.1x | --- |
Bionomics Ltd | 4.8M | 0.0x | --- |
Hepion Pharmaceuticals Inc | 4.8M | -0.1x | --- |
Raphael Pharmaceutical Inc | 4.9M | -4.9x | --- |
Company Information
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NYMOZARFEX, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company also has a patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications. It also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke.
Contact Information
- Headquarters
- St. Laurent,Suite 306 9900 Cavendish BlvdSAINT-LAURENT, QC, Canada H4M 2V2
- Phone
- 800-936-9669
- Fax
- 514-332-2227
Executives
- Chairman of the Board, President, Chief Executive Officer
- Paul Averback
- Vice President, General Counsel, Director
- Patrick Doody
- Independent Director
- David Morse
- Independent Director
- James Robinson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 93.5M |
Nymox Pharmaceutical Corp does not pay a dividend. | |
Beta | 8.91 |
EPS | $-0.10 |
Book Value | $-0.03 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
